Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Elderly Patients with Metastatic Colorectal Cancer
NCT02788006Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Percentage of Patients With a Tumoral Control Rate at 2 Months. Started Jan 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT02788006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788006.